US 12,465,602 B2
Use of an opioid molecule for treating dry eye and eyes suffering from allergies
Gaëtan Terrasse, Dijon (FR); and Catherine Bur, Dijon (FR)
Assigned to H4 ORPHAN PHARMA, Dijon (FR); and Gaëtan Terrasse, Dijon (FR)
Appl. No. 17/617,246
Filed by H4 ORPHAN PHARMA, Dijon (FR); and Gaëtan Terrasse, Dijon (FR)
PCT Filed Jun. 5, 2020, PCT No. PCT/EP2020/065610
§ 371(c)(1), (2) Date Dec. 7, 2021,
PCT Pub. No. WO2020/245345, PCT Pub. Date Dec. 10, 2020.
Claims priority of application No. 1906077 (FR), filed on Jun. 7, 2019.
Prior Publication US 2022/0233517 A1, Jul. 28, 2022
Int. Cl. A61P 27/02 (2006.01); A61K 31/4741 (2006.01); A61K 31/728 (2006.01); A61K 31/78 (2006.01); A61P 37/08 (2006.01)
CPC A61K 31/4741 (2013.01) [A61P 27/02 (2018.01)] 5 Claims
 
1. A method of treating dry eye disease comprising administering (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3] dioxolo [4,5-g] isoquinolin-5-yl]-3H-2-benzofuran-1-one, its enantiomer, or a pharmaceutically-acceptable salts thereof, to a patient in need.